101 related articles for article (PubMed ID: 28276170)
21. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
[TBL] [Abstract][Full Text] [Related]
22. Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
Fiala O; Pesek M; Finek J; Topolcan O; Racek J; Svaton M; Kucera R; Minarik M; Benesova L; Bortlicek Z; Chloupkova R; Poprach A; Buchler T
Anticancer Res; 2016 May; 36(5):2459-65. PubMed ID: 27127158
[TBL] [Abstract][Full Text] [Related]
23. Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma.
Fan S; Guan Y; Zhao G; An G
Thorac Cancer; 2018 Jan; 9(1):146-151. PubMed ID: 29131503
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
[TBL] [Abstract][Full Text] [Related]
25. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation.
Osterlind K; Andersen PK
Cancer Res; 1986 Aug; 46(8):4189-94. PubMed ID: 3015384
[TBL] [Abstract][Full Text] [Related]
27. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
28. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
29. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer.
Omar M; Tanriverdi O; Cokmert S; Oktay E; Yersal O; Pilancı KN; Menekse S; Kocar M; Sen CA; Ordu C; Goksel G; Meydan N; Barutca S;
Clin Respir J; 2018 Mar; 12(3):922-929. PubMed ID: 28026133
[TBL] [Abstract][Full Text] [Related]
30. Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.
Inomata M; Hayashi R; Tokui K; Taka C; Okazawa S; Kambara K; Ichikawa T; Yamada T; Miwa T; Kashii T; Matsui S; Tobe K
Tumori; 2016 Dec; 102(6):606-609. PubMed ID: 26429641
[TBL] [Abstract][Full Text] [Related]
31. Total lactate dehydrogenase and its isoenzymes in serum of patients with non-small-cell lung cancer.
Rotenberg Z; Weinberger I; Sagie A; Fuchs J; Davidson E; Sperling O; Agmon J
Clin Chem; 1988 Apr; 34(4):668-70. PubMed ID: 2834116
[TBL] [Abstract][Full Text] [Related]
32. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.
Liu R; Cao J; Gao X; Zhang J; Wang L; Wang B; Guo L; Hu X; Wang Z
Tumour Biol; 2016 Oct; 37(10):14083-14088. PubMed ID: 27511116
[TBL] [Abstract][Full Text] [Related]
33. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
[TBL] [Abstract][Full Text] [Related]
34. Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact.
Aarts MJ; Aerts JG; van den Borne BE; Biesma B; Lemmens VE; Kloover JS
Clin Lung Cancer; 2015 Jul; 16(4):282-91. PubMed ID: 25572007
[TBL] [Abstract][Full Text] [Related]
35. Endothelial activation and stress index (EASIX) as a predictive biomarker in small cell lung cancer.
Go SI; Park S; Kang MH; Kim HG; Kang JH; Kim JH; Lee GW
Cancer Biomark; 2022; 35(2):217-225. PubMed ID: 36120771
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer.
Wang X; Jiang R; Li K
Cell Biochem Biophys; 2014 Jul; 69(3):633-40. PubMed ID: 24554485
[TBL] [Abstract][Full Text] [Related]
37. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
[TBL] [Abstract][Full Text] [Related]
38. Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients.
Cai Q; Luo HL; Gao XC; Xiong CJ; Tong F; Zhang RG; Hu Y; Wu G; Dong XR
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):916-922. PubMed ID: 27924504
[TBL] [Abstract][Full Text] [Related]
39. High pretreatment serum C-reactive protein level predicts a poor prognosis for combined small-cell lung cancer.
Shao N; Cai Q
Tumour Biol; 2015 Nov; 36(11):8465-70. PubMed ID: 26026588
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort.
Ding N; Pang Z; Shen H; Ni Y; Du J; Liu Q
Sci Rep; 2016 Oct; 6():34823. PubMed ID: 27703265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
